Suggestions
Stig Hansen
Co-founder, President, and CEO, Kimia Therapeutics, Inc.
Stig Hansen is an accomplished professional with a strong educational background in Molecular Biology, Neuroscience, and Biochemistry.
He studied for his Post-Doc and Visiting Scholar in Molecular Biology and Neuroscience at the University of California, Berkeley, further enhancing his expertise in the field.
Prior to this, Stig Hansen pursued his Ph.D. in Molecular and Cell Biology at Københavns Universitet - University of Copenhagen, and obtained his Master of Science in Biochemistry from the same esteemed institution.
Stig Hansen has held key positions in various prominent organizations, showcasing his leadership and strategic skills.
He was the Co-founder, President, and CEO at Kimia Therapeutics, demonstrating his entrepreneurial spirit and ability to drive success in the industry.
Additionally, he served as a Member of the Board of Directors, as well as the Co-founder and CEO, at Carmot Therapeutics, Inc., illustrating his versatile capabilities in different roles within the biotech sector.
His professional journey also includes the role of Associate Director of Biology at Sunesis Pharmaceuticals, adding to his rich experience and expertise in the pharmaceutical industry.
Highlights
I’m delighted to congratulate the entire Kimia team on the close of the $55M Series A that was announced today. Over the past several months, the Kimia team has done a phenomenal job getting the company off the ground. Also a big thanks to our supportive investors. I very much look forward to working with all of you and to sharing the journey ahead of us. Together, we will build out the ATLAS platform and create a chemical map of the druggable proteome, identify novel sites for therapeutic intervention, and accelerate the discovery of new and better medicines. To learn more please visit our new website: www.kimiatx.com Stig
I would like to congratulate the entire Carmot team – past and present - on the merger with Roche that was announced today. Without your dedication and excellent work, we would not have gotten to where we are. Thanks for all your hard work and you should be proud of what you have accomplished. I’m delighted that the merger with Roche will provide the technical and financial resources needed to bring these transformative therapies to patients faster. To make what matters possible for patients! Kudos to the entire Carmot team - this is a great achievement and a significant deal that ranks 5th among all private biotech acquisitions, ever!
